Japanese Pharmacology & Therapeutics（JPT）
Vol. 27 No. 3 1999
* With abstract in English ** In English
▲Japanese version：Ensuring good statistical practical research
―Guidelines for standard operating procedures(an update)―
Philip M. North
Jpn Pharmacol Ther 1999 27(3) 241-58
Effect of pibutidine hydrochloride, a histamine H2-receptor antagonist, on gastric acid secretion and ulcer formation-induced by various experimental model in rats
Y. Isobe, et al.
Jpn Pharmacol Ther 1999 27(3) 261-71*
Anti-secretory and anti-ulcer effect of pibutidine hydrochloride, histamine H2-receptor antagonist, in rats
Y. Isobe, et al.
Jpn Pharmacol Ther 1999 27(3) 273-80*
Effect of pibutidine, histamine H2-receptor antagonist, on ［14C］ aminopyrine accumulation in rabbit isolated parietal cells
Y. Isobe, et al.
Jpn Pharmacol Ther 1999 27(3) 281-7*
Protective effect of pibutidine hydrochloride on the gastric mucosal lesions in rats
Y. Kiuchi, et al.
Jpn Pharmacol Ther 1999 27(3) 289-93*
Effect of a histamine H2-receptor antagonist pibutidine hydrochloride on the healing of acetic acid-induced gastric ulcer
H. Kijima, et al.
Jpn Pharmacol Ther 1999 27(3) 295-302*
Involvement of nitric oxide in the curative effect of a histamine H2-receptor antagonist pibutidine hydrochloride on the acetic acid-induced gastic ulcer in rats
S. Kajita, et al.
Jpn Pharmacol Ther 1999 27(3) 303-6*
Effect of a histamine H2-receptor antagonist pibutidine hydrochloride on the mitogenic activity and epidermal growth factor content in the rat gastric juice
T. Saito, et al.
Jpn Pharmacol Ther 1999 27(3) 307-13*
Single dose toxicity studies of 3-amino-4-［［(Z)-4-［［4-(piperidinomethyl)-2-pyridyl］oxy］-2-butenyl］amino］-3-cyclobutene-1,2-dione monohydrochloride (pibutidine hydrochloride) in mice, rats and dogs
S. Nakagawa, et al.
Jpn Pharmacol Ther 1999 27(3) 315-29*
Repeated dose toxicity study of 3-amino-4-［［(Z)-4-［［4-(piperidinomethyl)-2-pyridyl］oxy］-2-butenyl］amino］-3-cyclobutene-1,2-dione monohydrochloride (pibutidine hydrochloride) in rats(1)
―13-Week oral toxicity study with 4-week recovery test―
T. Ohshima, et al.
Jpn Pharmacol Ther 1999 27(3) 331-45*
Repeated dose toxicity study of 3-amino-4-［［(Z)-4-［［4-(piperidinomethyl)-2-pyridyl］oxy］-2-butenyl］amino］-3-cyclobutene-1,2-dione monohydrochloride (pibutidine hydrochloride) in rats(2)
―52-Week oral toxicity study in rats with 5-week recovery test―
M. Sugiura, et al.
Jpn Pharmacol Ther 1999 27(3) 347-74*
Reproductive and developmental toxicity studies of 3-amino-4-［［(Z)-4-［［4-(piperidinomethyl)-2-pyridyl］oxy］-2-butenyle?］amino］-3-cyclobutene-1,2-dione monohydrochloride (pibutidine hydrochloride) (1)
―Fertility study in rats―
T. Inoue, et al.
Jpn Pharmacol Ther 1999 27(3) 375-84*
Reproductive and developmental toxicity studies of 3-amino-4-［［(Z)-4-［［4-(piperidinomethyl)-2-pyridyl］oxy］-2-butenyl］amino］-3-cyclobutene-1,2-dione monohydrochloride (pibutidine hydrochloride) (2)
―Teratogenicity study in rats―
T. Inoue, et al.
Jpn Pharmacol Ther 1999 27(3) 385-400*
Reproductive and developmental toxicity studies of 3-amino-4-［［(Z)-4-［［4-(piperidinomethyl)-2-pyridyl］oxy］-2-butenyl］amino］-3-cyclobutene-1,2-dione monohydrochloride (pibutidine hydrochloride) (3)
―Teratogenicity study in rabbits―
T. Inoue, et al.
Jpn Pharmacol Ther 1999 27(3) 401-8*
Reproductive and developmental toxicity studies of 3-amino-4-［［(Z)-4-［［4-(piperidinomethyl)-2-pyridyl］oxy］-2-butenyl］amino］-3-cyclobutene-1,2-dione monohydrochloride (pibutidine hydrochloride) (4)
―Prenatal and postnatal study in rats―
T. Inoue, et al.
Jpn Pharmacol Ther 1999 27(3) 409-22*
Antigenicity study of 3-amino-4-［［(Z)-4-［［4-(piperidinomethyl)-2-pyridyl］oxy］-2-butenyl］amino］-3-cyclobutene-1,2-dionemonohydrochloride (pibutidine hydrochloride)
F. Kawamura, et al.
Jpn Pharmacol Ther 1999 27(3) 423-30*
Mutagenicity studies of 3-amino-4-［［(Z)-4-［［4-(piperidinomethyl)-2-pyridyl］oxy］-2-butenyl］amino］-3-cyclobutene-1,2-dione monohydrochloride (pibutidine hydrochloride)
K. Ohsawa, et al.
Jpn Pharmacol Ther 1999 27(3) 431-9*
Effects of lafutidine on development of mucosal lesions and changes in transmucosal potential difference induced by monochloramine in rat stomachs
M. Umeda, et al.
Jpn Pharmacol Ther 1999 27(3) 441-9*
Phase I safety study of interferon alfacon-1 in healthy volunteers
―Pharmacodynamic response―
J. Azuma
Jpn Pharmacol Ther 1999 27(3) 451-60**
Clinical efficacy and safety of pirmenol patients of arrhythmia with organic heart diseases
A. Chishaki, et al.
Jpn Pharmacol Ther 1999 27(3) 461-72*
Late phase II study of sepimostat mesilate (FUT-187) in postgastrectomy reflux esophagitis
―Clinical optimum dose in a double blind study―(revised report)
O. Abe, et al.
Jpn Pharmacol Ther 1999 27(3) 473-87*
Clinical evaluation of the OTC product K98-01 (KINKAN) on the shoulder stiffness, backache, confusion, sprain
F. Fukuhara, et al.
Jpn Pharmacol Ther 1999 27(3) 489-96